These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 16299025)

  • 1. Life threatening intra-abdominal sepsis in patients on anti-TNF-alpha therapy.
    Goode S; Tierney G; Deighton C
    Gut; 2006 Apr; 55(4):590-1. PubMed ID: 16299025
    [No Abstract]   [Full Text] [Related]  

  • 2. Mesenteric and splenic cat-scratch disease during etanercept therapy.
    Schiffmann A; Pers YM; Lukas C; Combe B; Morel J
    Rheumatology (Oxford); 2009 Nov; 48(11):1461-2. PubMed ID: 19690129
    [No Abstract]   [Full Text] [Related]  

  • 3. Do TNF-blockers reduce or induce uveitis?
    Cobo-Ibáñez T; del Carmen Ordóñez M; Muñoz-Fernández S; Madero-Prado R; Martín-Mola E
    Rheumatology (Oxford); 2008 May; 47(5):731-2. PubMed ID: 18346974
    [No Abstract]   [Full Text] [Related]  

  • 4. Uveitis and tumour necrosis factor blockade in ankylosing spondylitis.
    Coates LC; McGonagle DG; Bennett AN; Emery P; Marzo-Ortega H
    Ann Rheum Dis; 2008 May; 67(5):729-30. PubMed ID: 18408116
    [No Abstract]   [Full Text] [Related]  

  • 5. Severe refractory rheumatoid arthritis successfully treated with combination rituximab and anti-tumor necrosis factor-alpha-blocking agents.
    Koumakis E; Wipff J; Avouac J; Kahan A; Allanore Y
    J Rheumatol; 2009 Sep; 36(9):2125-6. PubMed ID: 19738227
    [No Abstract]   [Full Text] [Related]  

  • 6. Anti-tumour necrosis factor-alpha therapy increases body weight in patients with chronic plaque psoriasis: a retrospective cohort study.
    Gisondi P; Cotena C; Tessari G; Girolomoni G
    J Eur Acad Dermatol Venereol; 2008 Mar; 22(3):341-4. PubMed ID: 18005022
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-tumor necrosis factor therapy: 6 year experience of a single center in northern Israel and possible impact of health policy on results.
    Braun-Moscovici Y; Markovits D; Rozin A; Toledano K; Nahir AM; Balbir-Gurman A
    Isr Med Assoc J; 2008 Apr; 10(4):277-81. PubMed ID: 18548981
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effective co-administration of infliximab and etanercept following the failure of sequential anti-TNF agents in a patient with HLA-B27-associated arthropathy.
    Sheehy C; Murphy E; Barry M
    Rheumatology (Oxford); 2006 Oct; 45(10):1314-5. PubMed ID: 16837474
    [No Abstract]   [Full Text] [Related]  

  • 9. Increase in plasma levels of adiponectin after administration of anti-tumor necrosis factor agents in patients with rheumatoid arthritis.
    Nagashima T; Okubo-Fornbacher H; Aoki Y; Kamata Y; Kimura H; Kamimura T; Nara H; Iwamoto M; Yoshio T; Okazaki H; Minota S
    J Rheumatol; 2008 May; 35(5):936-8. PubMed ID: 18464318
    [No Abstract]   [Full Text] [Related]  

  • 10. Anti-tumour necrosis factor agents and lipid profile: a class effect?
    Garcês SP; Parreira Santos MJ; Vinagre FM; Roque RM; da Silva JA
    Ann Rheum Dis; 2008 Jun; 67(6):895-6. PubMed ID: 18474660
    [No Abstract]   [Full Text] [Related]  

  • 11. TNF-alpha antagonists: pulmonary legionellosis.
    Prescrire Int; 2007 Feb; 16(87):20. PubMed ID: 17326282
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-tumor necrosis factor therapy increases synovial osteoprotegerin expression in rheumatoid arthritis.
    Catrina AI; af Klint E; Ernestam S; Catrina SB; Makrygiannakis D; Botusan IR; Klareskog L; Ulfgren AK
    Arthritis Rheum; 2006 Jan; 54(1):76-81. PubMed ID: 16385498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TNF inhibition in SLE: where do we stand?
    Aringer M; Smolen JS
    Lupus; 2009 Jan; 18(1):5-8. PubMed ID: 19074162
    [No Abstract]   [Full Text] [Related]  

  • 14. [Increased risk of infection with biological immunomodifying antirheumatic agents. Clear guidelines are necessary as shown by case reports].
    Söderlin M; Blomkvist C; Dahl P; Forsberg P; Fohlman J
    Lakartidningen; 2005 Dec 5-11; 102(49):3794-6, 3799-800. PubMed ID: 16408703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-TNF therapy in the management of Behcet's disease--review and basis for recommendations.
    Sfikakis PP; Markomichelakis N; Alpsoy E; Assaad-Khalil S; Bodaghi B; Gul A; Ohno S; Pipitone N; Schirmer M; Stanford M; Wechsler B; Zouboulis C; Kaklamanis P; Yazici H
    Rheumatology (Oxford); 2007 May; 46(5):736-41. PubMed ID: 17403712
    [No Abstract]   [Full Text] [Related]  

  • 16. Assessment of pain in rheumatoid arthritis: minimal clinically significant difference, predictors, and the effect of anti-tumor necrosis factor therapy.
    Wolfe F; Michaud K
    J Rheumatol; 2007 Aug; 34(8):1674-83. PubMed ID: 17611989
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cutaneous T-cell lymphoma following treatment of rheumatoid arthritis with tumour necrosis factor-alpha blocking agents: two cases.
    Lourari S; Prey S; Livideanu C; Jamard B; Lamant L; Cantagrel A; Paul C
    J Eur Acad Dermatol Venereol; 2009 Aug; 23(8):967-8. PubMed ID: 19192017
    [No Abstract]   [Full Text] [Related]  

  • 18. Maintaining and optimising anti-TNF therapy.
    Somerville M
    Musculoskeletal Care; 2007 Dec; 5 Suppl 1():1-17. PubMed ID: 18050263
    [No Abstract]   [Full Text] [Related]  

  • 19. Pulsating back pain associated with tumor necrosis factor-alpha blockade.
    Rozin AP; Braun-Moscovici Y; Balbir-Gurman A
    Ann Pharmacother; 2008 Dec; 42(12):1912-3. PubMed ID: 19033477
    [No Abstract]   [Full Text] [Related]  

  • 20. Anti-tumour necrosis factor treatment in patients with refractory systemic vasculitis associated with rheumatoid arthritis.
    Puéchal X; Miceli-Richard C; Mejjad O; Lafforgue P; Marcelli C; Solau-Gervais E; Steinfeld S; Villoutreix C; Trèves R; Mariette X; Guillevin L;
    Ann Rheum Dis; 2008 Jun; 67(6):880-4. PubMed ID: 18037625
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.